Emerging and Evolving Ovarian Cancer Animal Models by Bobbs, Alexander S. et al.
29CanCer Growth and Metastasis 2015:8(s1)
Emerging and Evolving Ovarian Cancer Animal Models
Supplementary Issue: Animal Models of Cancer Biology
alexander s. Bobbs1,2, Jennifer M. Cole1,2 and Karen d. Cowden dahl1–4
1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-South Bend, South Bend, IN, USA.  
2Harper Cancer Research Institute, South Bend, IN, USA. 3Department of Chemistry and Biochemistry, University of Notre Dame,  
Notre Dame, IN, USA. 4Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
ABSTR ACT: Ovarian cancer (OC) is the leading cause of death from a gynecological malignancy in the United States. By the time a woman is diagnosed 
with OC, the tumor has usually metastasized. Mouse models that are used to recapitulate different aspects of human OC have been evolving for nearly 
40 years. Xenograft studies in immunocompromised and immunocompetent mice have enhanced our knowledge of metastasis and immune cell involvement 
in cancer. Patient-derived xenografts (PDXs) can accurately reflect metastasis, response to therapy, and diverse genetics found in patients. Additionally, 
multiple genetically engineered mouse models have increased our understanding of possible tissues of origin for OC and what role individual mutations play 
in establishing ovarian tumors. Many of these models are used to test novel therapeutics. As no single model perfectly copies the human disease, we can use 
a variety of OC animal models in hypothesis testing that will lead to novel treatment options. The goal of this review is to provide an overview of the utility 
of different mouse models in the study of OC and their suitability for cancer research.
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Introduction
Every year in the United States, over 22,000 women are diag-
nosed with ovarian cancer (OC) and more than 15,000 die 
from the disease.1 The poor prognosis for women diagnosed 
with OC is largely because of the presence of local and distant 
metastases in 81% of patients at diagnosis, leading to 5-year 
survival rates of 69% and 30%, respectively.1 These numbers 
suggest that both early detection and treatment of metastatic 
disease are crucial in managing OC. These facts also highlight 
the need to better understand mechanisms driving progres-
sion from primary tumor to metastatic disease.
Ovarian tumors can arise in the ovary from germ cells, 
stromal cells, or epithelial cells. The vast majority (90%) of 
OC arises from epithelial tissue. There are several distinct his-
totypes of epithelial OC. They are high-grade serous (HGS) 
and low-grade serous ovarian, mucinous, endometrioid, clear 
cell, and transitional or undifferentiated.2 HGS is the most 
common form of OC. The high mortality associated with 
OC is a direct result of the process of tumor metastasis. OC 
invasion is a complex process that differs from metastatic pro-
grams of other solid tumors, since OC tumor cells shed from 
the primary site and spread throughout the peritoneal cavity 
without first entering the blood or lymphatic system.3 OC 
was originally thought to be derived from the ovarian surface 
epithelium.4 However, epidemiological, pathological, and 
molecular studies have made scientists question the origin of 
OC and hypothesize that different types of ovarian tumors 
may arise from different precursor cells, including those from 
the fallopian tube, endometrium, cervix, and gastrointestinal 
(GI) tract.2,5–7 In addition to the OC subtypes being histo-
logically different, they are also genetically distinct. Ovarian 
tumors have been divided into two classes. (1) Type 1 cancers 
progress from tumors with lower malignant activity, are usu-
ally low grade, and contain Ras pathway mutations; these 
include clear cell, mucinous, endometrioid, and low-grade 
serous tumors. (2) Type 2 tumors arise rapidly de novo and 
contain TP53 mutations; these include HGS, undifferenti-
ated, and carcinosarcomas.8 Recent work suggests that some 
HGS tumors may be initiated in the fimbria of the fallopian 
tube.8,9 Identifying the cell type of origin for OC will change 
how animal models are generated and evaluated.
The cause of mortality from most solid tumors is metas-
tasis. Frequently, as OC progresses, tumor cells accumulate 
as single-cell and multi-cell aggregates in the ascites fluid.10 
The accumulation of ascites fluid in late stage cancer correlates 
with poor outcome.11 These shed tumor cells metastasize 
locally. Preferred sites of metastasis include the omentum, 
peritoneal wall, the diaphragm, and small bowel mesentery.3 
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Therefore, design and utilization of mouse models of OC that 
recapitulate the steps of metastasis are critical. Here, we will 
review many of the common ways OC is studied in mice. We 
will first discuss xenografts derived from cell lines and patient 
samples, followed by genetic models of OC.
Xenograft Models of OC
Xenograft models are a common way of investigating OC 
growth, metastasis, and treatment response in a live animal. 
The process of injecting ovarian tumor cells into mice and 
monitoring tumor growth has been conducted since at least 
the early 1980s. In these early studies, the thymus of the mice 
was removed, mice were treated with cytosine arabinoside, 
given whole-body irradiation, and then engrafted subcutane-
ously (SC) with either ovarian ascites (n = 5) or a solid perito-
neal metastasis from a papillary cystadenocarcinoma ovarian 
tumor biopsy (n  =  8).12 Four of the peritoneal metastases 
established tumor growth.12 Xenograft studies have been used 
extensively since the 1980s and offer many advantages. Xeno-
grafts are effective at measuring tumor growth in response to 
mutations or exogenous gene expression. They allow for vali-
dation of therapies and studies of drug resistance. Xenografts 
also can faithfully recapitulate aspects of ovarian tumor pro-
gression and metastasis. However, xenografts do not recapitu-
late the initial transforming events leading to tumorigenesis. 
Furthermore, many xenograft mouse models are conducted 
using immunocompromised mice, which will lack the contri-
bution of the full complement of immune cells to the tumor 
growth process.
The use of xenograft models enables researchers to test 
factors that influence tumor growth, spread, and drug response 
in a live animal. These elements cannot be entirely recapitu-
lated in tissue culture. To study tumor growth in mice, murine 
or human OC cells are injected into mice. Cells from different 
genetic backgrounds are injected into immunocompromised 
mice such as Nude (Foxn1, Nu/Nu), SCID, NOD/SCID, or 
NOD-scid IL2Rcnull (NSG) to enable the cells to engraft 
without being eliminated by the immune system. Cells are 
injected SC, intraperitoneally (IP), or intrabursally [(IB) into 
the bursa that surrounds the mouse ovary]. The SC model is 
not well suited for ovarian metastasis studies as the tumors do 
not typically metastasize, and the tumor is not positioned in 
the right anatomic location or microenvironment. One advan-
tage of the SC model is that it is well suited for investiga-
tion with imaging modalities such as two-photon microscopy 
(Fig. 1). In two-photon microscopy, tumor vasculature (with 
fluorescent dextrans), collagens (with second harmonic imag-
ing), and fluorescently labeled tumor cells can be measured 
simultaneously in a live animal. This cannot be done with IP 
or IB injections because of the depth of the tumors. However, 
IP and IB tumors can be imaged in live animals with opti-
cal imaging approaches using fluorescence or luminescence. 
In contrast to SC tumors, IP and IB injections of tumor cells 
into mice can mimic aspects of tumor metastasis, particularly 
metastatic dissemination. While IP injection cannot mimic 
the initial steps in metastasis, IP-injected tumor cells such 
as SKOV3 metastasize to the ovary, peritoneal wall, dia-
phragm, and form ascites fluid similar to human disease.13 The 
SKOV3IP cell line is derived from ascites cells that developed 
in a mouse IP cavity injected with SKOV3 cells.13 Compared 
to the parental SKOV3 cells, the SKOV3IP cells grow faster, 
disseminate more, and exhibit overexpressed ERBB2.13 Many 
cells (including the SKOV3 lines) are frequently transfected or 
transduced with fluorescence or luminescence-expressing vec-
tors to monitor tumor growth in vivo.14 Similarly, OVCAR3 
cells metastasize to the GI tract, omentum, pancreas, kidney, 
and liver (unpublished data) when injected IP. In some ways, 
the IB injection mimics the initial steps in metastasis, as the 
tumor cells exit the bursa to spread throughout the perito-
neal cavity. Many cell lines metastasize following IB injec-
tion, including A2780, SKOV3, and HEY cells.15,16 Sites of 
metastasis include diaphragm, mesentery, bowel, and liver.16 
In particular, the A2780 cells have been used to study not only 
metastasis but also chemoresistance. A2780 that are sensitive 
to cisplatin and a subline of A2780 cells that are resistant to 
cisplatin cells are also commonly used in xenograft studies of 
chemoresistance in vivo.17 Many other cell lines not discussed 
also demonstrate growth in xenograft models.18
Compared to genetic models, xenograft models may 
require less time to form tumors, from a few weeks to a few 
months, depending on the cell line and the number of injected 
tumor cells. Tumor cells can be genetically manipulated in 
Figure 1. two-photon microscopy image of sKoV3iP tumor expressing 
green fluorescent protein (GFP). SKOV3IP labeled with GFP were 
injected sC into nude mice. after one week, two-photon microscopy was 
conducted to image tumor cells (green), collagen (blue), and vasculature 
(red). therefore, imaging subcutaneous tumor can provide information 
about how genetic variation affects tumor microenvironment.
Ovarian cancer animal models 
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culture, and then implanted in mice (Fig. 2). This allows for 
the study of how individual genes impact tumor development 
or metastasis. However, by using xenografts in immunocom-
promised mice to study OC, the response of the immune 
system is ignored.19 A thematically related model of OC is 
patient-derived xenografts (PDXs). To derive PDXs, ovar-
ian tumors are isolated from patients, and then surgically 
grafted or injected into mice. This system provides distinct 
advantages over using traditional xenografts with cell lines. 
Tumors from diverse genetic backgrounds can be grafted, 
and the tumor growth can be monitored. Furthermore, the 
PDXs recapitulate aspects of OC like metastasis and ascites 
formation. Typically, small fragments of a tumor are isolated 
and injected SC or orthotopically into immune compromised 
mice. Tumor engraftment percentages and time to develop 
tumors vary widely,19 and some xenograft studies result in less 
than 50% of the mice developing tumors.20 After the tumor 
reaches a critical size, it can be excised and reimplanted seri-
ally into subsequent mice. The original tumor and the serial 
PDX tumors are characterized for gene expression and muta-
tion profile to assess if the PDXs retain the genetics and 
behaviors of the original tumor.
PDX models are used to examine tumor progression and 
metastasis when the PDXs are implanted into the peritoneal 
cavity. In one model, human OC biopsies were dissociated and 
injected in NSG mice.21 The tumor aggregates that were injected 
contained tumor-associated cells, including lymphocytes and 
fibroblasts.21 These tumors metastasized to the omentum, 
ovary, pancreas, uterus, spleen, and liver. Ascites also developed 
in these mice. Twenty-six percent of mice were found to have 
lung micrometastases as commonly found in stage IV disease.21 
Furthermore, a large study of 241 tumors demonstrated that 
the PDXs retain the genetics and metastatic spreading pat-
tern of the original tumors.22 Minced tumors were injected 
IP into female SCID mice, and 74% (168) of these tumors 
engrafted, mostly in the pelvis.22 Almost 50% of the mice 
developed metastases in the intestines, mesentery, liver, spleen, 
diaphragm, and/or omentum, and 17 of these mice developed 
ascites.22 One intriguing study found that PDXs with ascites or 
plural effusions were more likely to generate xenograft tumors 
than solid tumors.23 This raises questions about the metastatic 
unit in OC. OC stem cells that have been isolated from serous 
adenocarcinomas based on surface expression of CD177 and 
CD44 were demonstrated to have increased tumorigenic capac-
ity in xenografts.24 A more recent study used a PDX model of 
OC to demonstrate that high expression type I receptor tyrosine 
kinase-like orphan receptor in OC stem cells results in higher 
tumorigenesis.21,25 More studies on the link between cancer 
stem cells and metastasis should be conducted using models like 
the PDXs to discover novel strategies to limit metastatic spread 
and appropriately target cells with metastatic potential.
One of the major advantages of the PDX models is the 
ability to investigate the response of tumors to therapeu-
tic agents. Treating PDX tumors with IL-12, FLT-3, and 
Figure 2. tumor cells can be genetically manipulated in culture, and then implanted in mice to form a tumor. Growth of the tumor can be measured as well 
as response to chemotherapy. Genetic models of cancer have increased our understanding of how oC originates and what mutations or combinations of 
mutations may lead to tumor establishment by disruption of tumor suppressor genes, introduction of oncogenes, and tumor origin manipulations. these 
provide valuable information on metastasis and highlight potential therapeutic targets.
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CD40 decreased tumor growth.26–28 Similarly, PDX tumors 
have been studied for their ability to predict patient response 
to drug therapy (previously reviewed by Scott et al).19 In one 
study, HGS tumors were engrafted into NGS mice with an 
83% success rate.29 After treatment with cisplatin, it was 
found that 40% of the mice were platinum sensitive, 30% were 
refractory, and 30% were platinum resistant.29 These responses 
correlated with patient outcome,29 which suggests that PDXs 
retain the genetic/epigenetic program of the original tumor 
and that the response to standard chemotherapy present in 
the original tumor is retained. Therefore, PDXs may someday 
be used to develop personalized patient treatment plans. One 
disadvantage of PDXs is the variable take rate of the tumors. 
Additionally, access to patient samples is an impediment to 
using PDXs as a model system.
Syngeneic mouse models of OC have also been devel-
oped. Murine ovarian surface epithelial cells from C57BL/6 
mice were transformed (ID8 cells), and then injected back 
into C57BL/6 mice so that tumor metastasis or growth can 
be monitored using mice with intact immune systems.30 
More recent syngeneic mouse models use cells with sponta-
neously generated increased aggressiveness to study resistance 
to anoikis.31 The tumors generated in this syngeneic model 
develop extensive metastasis in the peritoneal cavity reminis-
cent of advanced OC. McCloskey et al also described a strat-
egy for creating spontaneously transformed ovarian surface 
epithelial cell lines by maintaining cells for many passages. 
These transformed cells exhibited aberrant Wnt and NFKB 
signaling and resulted in tumors resembling HGS cancer 
when injected into the IP cavity of FVB/N mice.32 The synge-
neic experimental design more accurately reflects the response 
of the immune system during tumor progression than immu-
nocompromised models. However, the cells are of murine 
origin, and thus may not resemble human cancer as well as 
models using human cells.
Genetically Engineered Mouse Models of OC
Genetically engineered mouse models (GEMMs) have 
yielded many important advances in understanding cancer. 
Mouse models of leukemia, breast cancer, and colon cancer 
can faithfully recapitulate many aspects of human disease. The 
OC genetic models have been more complicated to generate, 
partially because of the lack of understanding of OC biology 
and the heterogeneity of OC. Infertility resulting from ovar-
ian tumors has also hampered generation of transgenic mod-
els of OC. The controversy about the cell type of origin for 
OC and identification of transgenic promoters that reflect the 
proper cell type of origin are further complications. GEMMs 
are especially important for studying the beginning stages of 
OC that cannot be mimicked in xenografts. Some OCs may 
originate in the fallopian tube, while others may arise from 
ovarian epithelium.5 Different GEMMs allow us to evalu-
ate how tumors arising from mutations at different anatomic 
locations compare to human disease. Thus, GEMMs provide 
an invaluable tool for studying the development of OC with 
mutations observed in patients. For example, women with 
familial Brca1 mutations have increased the risk of developing 
OC and develop cancer at a younger age than those with spo-
radic disease.33 Thus, mouse models with alterations to Brca1 
and other genes commonly mutated in OC, such as Tp53, 
c-Myc, Kras, Akt, and Brca2,34–36 are important to increasing 
our understanding regarding how genetic predisposition leads 
to OC (summarized in Table 1).
The most common mutation in HGS OC occurs in 
Tp53,37 which is mutated in about 48% of sporadic OCs and 
96% of HGS cancers.37,38 In addition, Rb1 is dysregulated in 
about 67% of HGS OCs.38 GEMMs can be used to study 
these tumor suppressors as well as oncogenes such as c-Myc, 
Kras, and Akt1. An early method for inhibiting both of Tp53 
and Rb1 is to express Simian virus 40 (SV40) large T anti-
gen that binds to and inactivates both p53 and pRB.39 Trans-
genic mice expressing SV40 under control of the promoter for 
Mullerian inhibiting substance type II receptor (MISIIR) 
develop poorly differentiated ovarian carcinomas.40 MISIIR 
is expressed in 92% of OC, but most nongynecological tissues 
do not express this receptor.41 These carcinomas express cyto-
keratins 8 and 19 and lack alpha-inhibin, suggesting that they 
are derived from epithelium and not derived from granulosa 
cells.40 These tumors result in ascites formation and metastatic 
spread to omentum.40 One mouse demonstrated metastasis to 
the kidney and one had metastasis to the uterus, but metastasis 
to other organs was not observed.40 This was the first pub-
lished model of a transgenic model of epithelial OC. A major 
disadvantage to this approach is that the mice were infertile 
because of the ovarian tumors. Therefore, other approaches to 
inactivate tumor suppressors that may be more indicative of 
human cancer needed to be developed.
Conditional knockouts of Tp53 and Rb1 have also 
been used to generate mouse models of OC. As reported 
by Flesken-Nikitin, mice with Tp53 and Rb1 flanked by 
loxP sites (floxed) were injected into the bursa ovary with 
an adenovirus expressing Cre recombinase under control 
of a CMV promoter.34 This double knockout resulted in a 
metastatic OC resembling human ovarian epithelial cancer, 
which spread to the lung, liver, and noninjected ovary.34 A 
total of 97% of the mice with knockout of Tp53 and Rb1 
in the ovary died within eight months.34 Single knockouts 
of either Tp53 or Rb1 were much less efficient at inducing 
metastatic cancer: 13% of Tp53 knockout mice and 3% of 
Rb1 knockout mice developed tumors.34 Importantly, these 
studies reveal that Tp53 mutations alone are sufficient for 
ovarian tumor initiation, but mutation in both Tp53 and Rb1 
lead to metastatic OC.34
In a more recent study, combinations of Tp53 mutation 
or loss, loss of pocket protein function, and loss of Brca1/2 
were generated to thoroughly examine the contributions 
of these genes to OC. Expression of T121 (a domain of the 
SV40 large T antigen) in the surface epithelium is induced 
Ovarian cancer animal models 
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by injecting Cre-expressing adenovirus (Adeno-Cre). T121 
is in a Cre-conditional loxP-GFP-stop-loxP (LSL) cassette 
driven by the cytokeratin 18 promoter. Injection of Adeno-
Cre resulted in inhibition of Rb1, p107, and p130, also known 
as the “pocket proteins.” In this study, antigen T121 is used in 
concert with floxed alleles for Tp53, a point mutation in Tp53 
(p53R172H), and inactivation of either Brca1 or Brca2.35 Inac-
tivation of the pocket proteins was sufficient for tumorigen-
esis, resulting in stage I serous epithelial OC.35 However, loss 
of pRb, p53, and Brca1 or Brca2 in mice more closely mimics 
serous OC.35 When Brca1 or Brca2 were deleted in this model 
(in addition to inhibition of Tp53 and the RB pathway), the 
tumors metastasized to the liver and demonstrated a gene 
expression profile resembling serous OC.35 A later version 
of this GEMM was used to study drug response in Brca1-
deficient mice, showing that tumors in these mice respond 
to a combination chemotherapy of cisplatin and olaparib.42 
This provides an example of how GEMMs can be used to 
test effective therapies. Through these varying combinations 
of genetic alterations, different stages of OC progression 
were modeled, from early stage I epithelial OC (Rb pathway 
disruption alone) to an advanced metastatic cancer (RB loss/
Tp53/Brca1/Brca2 alterations).
In addition to disrupting tumor suppressor genes, intro-
duction of oncogenes has also been employed to generate 
mouse models of OC. Transgenic mice expressing the avian 
retroviral receptor TVA (with a-actin or keratin 5 promoter) 
were generated.36 These mice were then crossed with p53 null 
mice.36 Ovarian surface epithelial cells were isolated from 
the mice and transduced in vitro with replication-competent 
avian-leukemia-virus splice-acceptor (RCAS)43 viral vectors. 
These viral vectors expressed common OC oncogenes: c-Myc, 
Kras, or Akt1. Subcutaneous tumor formation resulted when 
any two of these oncogenes were expressed in ovarian cells 
that were injected SC into nude mice.36 IB injection of the 
β-actin-TVA/p53−/− cells with the RCAS viruses contain-
ing c-Myc or Kras oncogenes resulted in metastastic OC.36 
Metastasis to the liver, spleen, intestine, kidney, and malig-
nant ascites was observed.36 This result mirrors that of later 
mouse models from the same laboratory, showing that TVA/
RCAS-induced expression of c-Myc is sufficient to induce 
transformation in ovarian cells from mice with floxed Tp53 
and Brca1.44 These transformed cells displayed chromosomal 
defects and an unusually high centromere count; injection 
of these modified cells into the ovary resulted in metastatic 
tumors that resemble serous ovarian carcinomas and spread to 
the peritoneum, pancreas, and intestines.44 Collectively, these 
models demonstrate that Tp53 mutation in concert with onco-
gene expression or loss of other tumor suppressors results in 
OC generation and metastasis.
As our understanding of the genetics and epigenetics of 
OC evolves, so must the ways of modeling the disease. It has been 
hypothesized that different cell types of origin and different 
genetic mutations are responsible for the distinct histological Ta
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subtypes of OC. Therefore, establishing models of fallopian 
tube and uterine-derived OC is essential. To determine if 
high-grade serous ovarian cancer (HGSOC) can originate 
from fallopian tube, Pax8-driven Cre recombinase was 
used to excise Brca1, Brca2, Tp53, and/or Pten.45 Loss of 
Brca1/2, Tp53 mutation, and Pten loss resulted in fallopian 
tube serous tubal intraepithelial carcinomas (STICs), ovar-
ian metastases, and peritoneal metastases.45 The histology, 
metastatic profile, and transcriptome of these tumors closely 
mimics HGS OC.45
Another method to transform the fallopian tube used 
SV40 large T antigen expressed under control of the Mullerian 
Ovgp-1 promoter.46 This model results in STICs and invasive 
adenocarcinomas that spread to the ovaries.46 Therefore, this 
model is capable of recapitulating early development of OC46 
in the fallopian tube. One additional advantage of this model 
is that the Ovgp-1 promoter ensures tissue-specific expression 
of SV40 in mice that have reached sexual maturity.
Since the ovary, uterus, and fallopian tube may be sites 
of origin for different types of OC, a comparison of trans-
formation at each of these locations was conducted. To com-
pare tumorigenesis in the ovary, oviduct, and endometrium 
using the same genetic backgrounds, a triple transgenic 
mouse model was created.47 In these mice, KrasG12D (using 
a LSL cassette) is induced, and floxed Pten is deleted using 
Adeno-Cre in different locations of the female reproduc-
tive tract.48 Additionally, these transgenic mice also express 
the human glycoprotein MUC1 that is often overexpressed 
in OC.48 Injection of Adeno-Cre into the ovary, oviduct, or 
uterus resulted in the formation of epithelial tumors capable 
of metastasis, spreading to the pancreas and diaphragm.47 
However, the nuclear grade of the tumors and survival of 
the mice varied depending on the anatomical site of injec-
tion.47 Tumors arising from ovaries, the oviduct, and uterus 
generated endometrioid histology and metastasis to spleen, 
diaphragm, and liver were detected.47 The oviduct tumors 
developed into poorly differentiated high-grade tumors, while 
ovarian and uterine tumors were more differentiated.47 Mice 
with ovarian and oviduct tumors exhibited the shortest mean 
survival times compared to mice with uterine tumors (89, 82, 
and 132.5 days, respectively). A key feature of this model is 
that overexpression of MUC1 results in a similar immune 
response as that seen in human patients.47 This enables test-
ing of immunotherapy treatments that target OC cells over-
expressing MUC1.47
 While many of the recent GEMMs are aimed at under-
standing the origin of OC or recapitulating HGSOC, mouse 
models of other OC histotypes have also emerged. Ovarian 
endometrioid adenocarcinoma is a subtype of OC originating 
from malignant uterine cells created during endometriosis.6 
Some models of endometrioid OC resulted from oncogenic 
Kras and a conditional Pten deletion.47,49 However, Kras 
mutations are uncommon in human endometrioid cancer. To 
address this issue, a mouse model of endometrioid OC was 
created in which Apc and Pten are deleted, since perturbations 
in Wnt and phosphoinositide 3-kinase (PI3K) signaling are 
linked in some endometrioid OC.50 Mice with floxed Apc and 
Pten were IB injected with Adeno-Cre.50 Resultant adenocar-
cinomas were similar to metastatic human ovarian endome-
trioid adenocarcinoma and50 were generally low grade, unlike 
those resulting from Tp53 mutations.50 The tumors resulting 
from Pten/Apc knockout showed increased nuclear β-catenin 
and overactive AKT signaling.50 These GEMMs have been 
used to test therapeutics against endometrioid cancer; a com-
bination of cisplatin and paclitaxel together with inhibitors 
of mTOR and AKT signaling has proven effective in mouse 
models.51 This work highlights the possibility of using treat-
ments that target the Wnt and PI3K pathways to combat 
endometrioid cancer.
Summary
The survival rates and treatment for OC have remained rela-
tively unchanged for the past two decades. Recent advances 
in understanding the genetic landscape of the histological 
subtypes of OC generate hope that targeted therapies can 
be devised that will increase patient survival. In order to 
see these targeted therapies come into practice, preclinical 
mouse models that reflect the genetics, metastatic potential, 
and different responses to therapy need to be used. In the last 
30 years, mouse models have progressed from early xeno-
grafts to xenografts with immunocompetant mice, and 
PDXs that reflect individual patient’s genetics and thera-
peutic response. Moreover, genetic models of cancer have 
increased our understanding of how OC originates and what 
mutations or combinations of mutations may lead to tumor 
establishment. A recent mouse model with mutations in c-Kit 
further allows the study of ovarian tumors in the context of 
a postmenopausal environment, potentially allowing for the 
above-discussed genetic mutations to be further improved by 
incorporating hormone responsiveness seen in the older popu-
lation most likely to be affected by OC.52 Now that we have a 
variety of mouse models (summarized in Table 2) (as well as 
other animal models, such as the laying hen)53 at our disposal 
that reflect a wide range of steps of OC progression, we can 
develop diagnostic, prognostic, and therapeutic approaches 
that will increase OC survival.
Abbreviations 
OC, ovarian cancer; GEMM, genetically engineered mouse 
model; PDX, patient-derived xenograft; HGS, high-grade 
serous; GI, gastrointestinal; HGSOC, high-grade serous 
ovarian cancer; IP, intraperitoneally; IB, intrabursally; SC, 
subcutaneously; STOSE, spontaneously transformed ovar-
ian surface epithelial; LSL, loxP-GFP-stop-loxP; MISIIR, 
Mullerian inhibiting substance type II receptor; RCAS, 
replication competent avian-leukemia-virus splice-accep-
tor; STIC, serous tubal intraepithelial carcinoma; SV40, 
Simian virus 40.
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